药店新零售东风劲吹 大参林构建智慧零售新生态

Core Insights - The pharmaceutical retail industry is undergoing significant transformation driven by continuous policy adjustments, diverse consumer health needs, and deep penetration of digital technologies [1][2][6] - Major trends in the industry include accelerated layout of dual-channel pharmacies, continuous expansion of DTP (Direct to Patient) pharmacies, and gradual improvement of new retail health service ecosystems [1][6] Policy Support - Recent policy changes have facilitated the development of new retail in pharmacies, including the gradual relaxation of online prescription drug sales, allowing consumers easier access to prescription medications [2] - The expansion of online medical insurance payment trials and the promotion of electronic medical insurance credentials have laid a solid foundation for large-scale online drug purchases [2] Omnichannel Integration - The company has established deep cooperation with O2O platforms such as Meituan, Ele.me, JD Daojia, and Tmall, leveraging their user traffic and delivery systems to expand online sales channels [3] - As of the end of 2024, the O2O delivery service coverage rate reached 80.38%, with a focus on user-centered 24-hour delivery services [3] - The company operates a membership system with over 100 million members, enhancing customer engagement through personalized health information and exclusive offers [3] Digital Upgrade - The company is piloting a "smart pharmacy" project, equipping stores with self-service drug dispensing machines and remote consultation screens to enhance customer convenience [4] - Integration of online and offline inventory systems allows for seamless "online ordering and in-store pickup" experiences for consumers [4] Multi-Dimensional Expansion - The company employs a "self-built + acquisition + direct franchise" model for store expansion, with a total of 16,622 stores nationwide as of March 31, 2025, including a net increase of 2,479 stores in 2024 [5] - The company has actively developed DTP pharmacies and slow disease management outlets, with 248 DTP pharmacies and 2,822 various medical insurance coordination stores by the end of 2024 [5] - The company has achieved significant revenue growth in the Northeast, North China, Southwest, and Northwest regions, with a revenue growth rate of 34.42% in these areas in 2024 [5] Future Outlook - The pharmaceutical retail market holds substantial potential, and the company aims to explore a business model integrating "medicine + health + care + testing + insurance" to provide comprehensive health solutions [6] - The company is committed to leading the industry towards a more diversified, professional, and intelligent direction, contributing to the advancement of China's pharmaceutical retail sector [6]